Izabela D. Fokt, Ph.D.

Peer-Reviewed Articles

1. Fokt ID, Sołtyka-Krajewska M, Marcin Ziemniak, Anna Zawadzka-Kazimierczuk, Paulina Skrzypczyk, Ewelina Siwiak-Niedbalska, Anna Jaskiewicz, Rafał Zielinski, Stanisław Skóra, Wiktor Kozminski, Krzysztof Wozniak, Waldemar Priebe, Beata Pajak-Tarnacka. Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model. Biomedicines 12(10), 2024. e-Pub 2024.
2. Fokt I, Cybulski M, Skora S, Pajak B, Ziemniak M, Wozniak K, Zielinski R, Priebe W. d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res 531:108861, 2023. e-Pub 2023. PMID: 37356236.
3. Ziemniak M, Pawledzio S, Zawadzka-Kazimierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Correction: X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(17):10306, 2022. e-Pub 2022. PMID: 35427095.
4. Ziemniak M, Pawledzio S, Zawadzka-Kazmierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(14):8345-8360, 2022. e-Pub 2022. PMID: 35424802.
5. Pajak B, Siwiak-Niedbalska E, Jaskiewicz A, Soltyka M, Zielinski R, Domoradzki T, Fokt I, Skóra S, Priebe W. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines 9(12), 2021. e-Pub 2021. PMID: 34944565.
6. Ziemniak M, Zawadzka-Kazimierczuk A, Pawledzio S, Malinska M, Soltyka M, Trzybinski D, Kozminski W, Skora S, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. Int J Mol Sci 22(7), 2021. e-Pub 2021. PMID: 33918425.
7. Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel) 13(4), 2020. e-Pub 2020. PMID: 32340173.
8. Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zielinski R, Priebe W. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs 35(5):545-555, 2017. e-Pub 2017. PMID: 28417283.
9. Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med 3(3):69-79, 2017. e-Pub 2017. PMID: 28825042.
10. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
11. Malińska, M, Fokt, I, Priebe, W, Woźniak, K. Bromine atom interactions in biologically active acrylamide derivatives. Crystal Growth and Design 15(6):2632-2642, 2015. e-Pub 2015.
12. Malinska M, Fokt I, Priebe W, Wozniak K. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth and Design 15(6):2632-2642, 2015. e-Pub 2015.
13. Cybulski, M, Formela, A, Fokt, I. N-Chlorophthalimide as a mild and efficient chlorination reagent in the Gassman ortho alkylation of aromatic amines. Synthesis of 3-(methylthio)oxindoles. Tetrahedron Letters 55(40):5423-5425, 2014. e-Pub 2014.
14. Cybulski M, Formela A, Fokt I. N-Chlorophthalimide as a mild and efficient chlorination reagent in the Gassman ortho alkylation of aromatic amines. Synthesis of 3-(methylthio)oxindoles. Tetrahedron Letters 55(40):5423-5425, 2014. e-Pub 2014.
15. Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta 1834(7):1292-1301, 2013. e-Pub 2013. PMID: 23523885.
16. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res 368:111-9, 2013. e-Pub 2013. PMID: 23376241.
17. Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther 13(8):657-70, 2012. e-Pub 2012. PMID: 22555804.
18. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 2012. e-Pub 2012. PMID: 22249692.
19. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
20. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117(13):2926-38, 2011. e-Pub 2011. PMID: 21692052.
21. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6(1):e16195, 2011. e-Pub 2011. PMID: 21283755.
22. Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One 6(9):e24397, 2011. e-Pub 2011. PMID: 21935404.
23. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 Enhances IFN-alpha Efficacy against Metastatic Melanoma in a Murine Model. Clin Cancer Res 9(9):OF1-OF12, 2010. e-Pub 2010. PMID: 20388845.
24. Conard C, Koul D, Guan S, Fokt I, Shen R, Ramnarian D, Madden T, Yung WKA, Atkinson J, Gilbertson R, Priebe W. Berubicin: a novel topoisomerase II inhibitor with activity in ependymoma. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, 2009. e-Pub 2009.
25. Fokt I, Szymanski S, Skora S, Cybulski M, Madden T, Priebe W. D-Glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2halo-D-glucoses and -D-mannoses. Carbohydr Res 344(12):1464-1473, 2009. e-Pub 2009. PMID: 19625015.
26. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58(7):1023-32, 2009. e-Pub 2009. PMID: 19002459.
27. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 2008. e-Pub 2008. PMID: 18794085.
28. Corvis Y, Korchowiec B, Korchowiec J, Badis M, Mironiuk-Puchalska E, Fokt I, Priebe W, Rogalska E. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B 112(35):10953-63, 2008. e-Pub 2008. PMID: 18698707.
29. Guha S, Chakraborty A, Kunnumakkara AB, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Aggarwal B, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2-STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. Gastrointest Cancer Research 2(4):205-208, 2008. e-Pub 2008.
30. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Fokt I, Piebe W. NFkappaB activation and drug sensitivity in human neoplastic cells treated with anthracyclines. Acta Pol Pharm 65(2):267-71, 2008. e-Pub 2008. PMID: 18666436.
31. Schroeder C, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, Priebe W. WP760, a new DNA-binding agent with unique melanoma selectivity. Molecular Cancer Therapeutics 6(12):3407S-3407S, 2007. e-Pub 2007.
32. Antonovic L, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. Inhibition of glycolysis and induction of autophagy in gliomas by 2-fluoro-deoxy-D-glucose. Molecular Cancer Therapeutics 6(12):3443S-3443S, 2007. e-Pub 2007.
33. Antonovic L, Johansen M, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. 2-Deoxy-D-glucose induces Type II cell death in pancreatic cancer. Molecular Cancer Therapeutics 6(12):3443S, Part 2, 2007. e-Pub 2007.
34. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67(20):9630-6, 2007. e-Pub 2007. PMID: 17942891.
35. Kong LY, Hussain SF, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients. Neuro-Oncology 9(4):507, 2007. e-Pub 2007.
36. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol 60(5):625-633, 2007. e-Pub 2007. PMID: 17195067.
37. Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25(4):313-26, 2007. e-Pub 2007. PMID: 17483874.
38. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz) 55(3):193-8, 2007. e-Pub 2007. PMID: 17557149.
39. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435-44, 2007. e-Pub 2007. PMID: 17043651.
40. Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73(5):620-31, 2007. e-Pub 2007. PMID: 17161827.
41. Bidwell P, Gene L, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubin. Biochemical Pharmacology 73(5):620-631, 2007. e-Pub 2007.
42. Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing 'hypoxic tumor cells'. Cancer Chemother Pharmacol 58(6):725-36, 2006. e-Pub 2006. PMID: 16555088.
43. Gruber BM, Anuszewska EL, Roman I, Gozdzik A, Priebe W, Fokt I. Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol Pharm 63(1):15-8, 2006. e-Pub 2006. PMID: 17515324.
44. Portugal J, Cashman DJ, Trent JO, Ferrer-Miralles N, Przewloka T, Fokt I, Priebe W, Chaires JB. A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem 48(26):8209-19, 2005. e-Pub 2005. PMID: 16366602.
45. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Priebe W, Fokt I. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res 25(3B):2193-8, 2005. e-Pub 2005. PMID: 16158963.
46. Fokt, I, Grynkiewicz, G, Skibicki, P, Przewloka, T, Priebe, W. New strategies towards synthesis of doxorubicin analogs. Polish Journal of Chemistry 79(2):349-359, 2005. e-Pub 2005.
47. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Priebe W, Fokt I. Constitutive activation of transcription factor NFkappaB as a possible marker of sensitivity of neoplastic cells to anthracyclines. Acta Pol Pharm 62(1):17-23, 2005. e-Pub 2005. PMID: 16022489.
48. Grynkiewicz G, Fokt I, Skibicki P, Przewloka T, Szeja W, Priebe W. Synthesis of 1-O-Silylated 3-Azido- and 3-N-Trifluoroacetamido-2,3,6-trideoxy-L-arabino and L-lyxo-hexapyranoses, Convenient Glycosyl Donors for Preparation of Anthracycline Antibiotics and Related DNA-Binding Agents. . Polish J. Chem 79:335-347, 2005. e-Pub 2005.
49. Fanale MA, Liu Y, McKenzie TS, Fokt I, Priebe W. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. Journal of Clinical Oncology 23(16):155S-155S, part 1, Suppl. S, 2005. e-Pub 2005.
50. Nair RR, Wang H, Jamaluddin MS, Fokt I, Priebe W, Boyd DD. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res 15(5):265-79, 2005. e-Pub 2005. PMID: 16261846.
51. Fokt I, Grynkiewicz G, Skibicki P, Przewloka T, Priebe W. New strategies towards synthesis of doxorubicin analogs. Polish Journal of Chemistry 79:349-359, 2005. e-Pub 2005.
52. Iwamaru A, Szymanski S, Fokt I. Inhibition of STAT3 by WP1066 a novel tyrosine kinase inhibitor in malignant glioma cells in vitro and in vivo. Clinical Cancer Research 11(24):9021S-9021S Part 2 Suppl. S, 2005. e-Pub 2005.
53. Fox KR, Webster R, Phelps RJ, Fokt I, Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem 271(17):3556-66, 2004. e-Pub 2004. PMID: 15317591.
54. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol 67(2):353-64, 2004. e-Pub 2004. PMID: 14698047.
55. Samochocka, K, Fokt, I, Anulewicz-Ostrowska, R, Przewloka, T, Mazurek, AP, Fuks, L, Lewandowski, W, Kozerski, L, Bocian, W, Bednarek, E, Lewandowska, H, Sitkowskiand, J, Priebe, W. Platinum(II) and palladium(II) complexes with methyl 3,4-diamino-2,3,4,6- tetradeoxy-α-L-lyxo-hexopyranoside. Dalton Transactions(11):2177-2183, 2003. e-Pub 2003.
56. Priebe, W, Fokt I, Lee S. Targeting glioblastoma with new DNA-binding agents. Clinical Cancer Research 9(16):6108S, 2003. e-Pub 2003.
57. Scholz CR, Thapar N, Johansen MJ, Fokt I. A sensitive and specific method for the determination of WP744, a mechanistically altered anthracycline in mouse, rat, dog, and human plasma by LC/MS/MS. Clinical Cancer Research 9:626S-6262S, 2003. e-Pub 2003.
58. Kruszewski M, Bouzyk E, Oldak T, Samochocka K, Fuks L, Lewandowski W, Fokt I, Priebe W. Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratog Carcinog Mutagen 23:1-11, 2003. e-Pub 2003. PMID: 12616592.
59. Madden T, Scholz CR, Thapar N, Fokt I. Preclinical pharmacokinetics of WP744, A novel promising anticancer agent. Clinical Cancer Research 9(16):6264S-6264S Part 2 Suppl S, 2003. e-Pub 2003.
60. Samochocka K, Fokt I, Anulewicz-Ostrowska R, Przewloka T, Mazurek AP, Fuks L, Lewandowski W, Kozerski L, Bocian W, Bednarek E, Lewandowska H, Sitkowski J, Priebe W. Platinum (II) and palladium (II) complexes with methyl 3,4-diamino-2,3,4,6-tetradeoxy-a-L-lyxo-hexopyranoside. Dalton Trans:2177-2183, 2003. e-Pub 2003.
61. Kong LY, Talpaz M, Priebe W, Fokt I. Novel tyrphostin analogues inhibit STAT3 activation and induce apoptosis in multiple hematological malignancies. Blood 102(11):204B-204B 4534 Part 2, 2003. e-Pub 2003.
62. Salerno M, Przewloka T, Fokt I, Priebe W, Garnier-Suillerot A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem Pharmacol 63(8):1471-9, 2002. e-Pub 2002. PMID: 11996888.
63. Priebe W, Evrony G, Fokt I, Lee S, Talpaz M, Donato NJ. WP744, A Novel Anthracycline Highly Active Against STI-571 Resistant Tumors. European Journal of Cancer 38 (Suppl. 7):419, 2002. e-Pub 2002.
64. Priebe W, Nagy Z, Stepkowski SM, Fokt I. Targeting Jak3 with small molecules to inhibit T-cell activity. European Journal of Cancer 38:353 Suppl, 2002. e-Pub 2002.
65. Grynkiewicz G, Achmatowicz O, Fokt I, Priebe W, Ramza J, Szechner B, Szeja W. Synthesis of natural and modified anthracycline antibiotics from acommon precursor: 3,4-di-O-acetyl-L-rhamnal. Wiadomosci Chemiczne 56:535-560, 2002. e-Pub 2002.
66. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 2001. e-Pub 2001. PMID: 11911247.
67. Priebe W, Fokt I, Kowalczyk T, Krawczyk M, Grynkiewicz G, Szeja W. Glycals and masked glycals. creation of structural diversity and biologically important libraries. Abstracts of papers, 221 st ACS National Meeting, San Diego, CA, United States, Aprl 1-5, 2001, Carb-077, 2001. e-Pub 2001.
68. Qu X, Trent JO, Fokt I, Priebe W, Chaires JB. Allosteric, chiral-selective drug binding to DNA. Proc Natl Acad Sci U S A 97(22):12032-7, 2000. e-Pub 2000. PMID: 11027298.
69. Fokt I, Bogusiak J, Szeja W. Synthesis of thioglycofuranosides. Carbohydrate Letters 3(3):191-197, 1998. e-Pub 1998.
70. Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem 40(3):261-6, 1997. e-Pub 1997. PMID: 9022792.
71. Leng, F, Savkur, R, Fokt, I, Przewloka, T, Priebe, W, Chaires, JB. Base specific and regioselective chemical cross-linking of daunorubicin to DNA. Journal of the American Chemical Society 118(20):X-4737, 1996. e-Pub 1996.
72. Chaires JB, Satyanarayana S, Suh D, Fokt I, Przewloka T, Priebe W. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 35(7):2047-53, 1996. e-Pub 1996. PMID: 8652545.
73. Leng, F, Savkur, R, Fokt, I, Przewloka, T, Priebe, W, Chaires, JB. Base specific and regioselective chemical cross-linking of daunorubicin to DNA. Journal of the American Chemical Society 118(20):4731-4738, 1996. e-Pub 1996.
74. Leng F, Savkur R, Fokt I, Przewloka T, Priebe W, Chaires JB. Base specific and regioselective chemical cross-linking of Daunorubicin to DNA. J. Am. Chem. Soc 118:4731-38, 1996. e-Pub 1996.
75. Bieg T, Bogusiak J, Szeja W, Fokt I, Grynkiewicz G, Niedzielski C, Przybysz B, Wandzik I. Alkylation of carbohydrates by phase-transfer catalysis. Pol. J. Appl. Chem 38:491-497, 1994. e-Pub 1994.
76. Fokt, I, Szeja, Wl. Synthesis 1-thioglycosides from 1-sulfenates. Carbohydrate Research 232(1):169-175, 1992. e-Pub 1992.
77. Szeja W, Fokt I, Niedzielski C, Grynkiewicz G. Reaction of sugar in the crystalline state. Zuckerind 117:481, 1992. e-Pub 1992.
78. Szeja W, Fokt I. Synthesis of 1-thioglycosides from 1-O-sulfenates. Carbohydrate Research 232:169-175, 1992. e-Pub 1992.
79. Fokt, I, Szeja, Wl. Synthesis of sulfenates of sugar derivatives. Carbohydrate Research 222(C):271-276, 1991. e-Pub 1991.
80. Szeja W, Fokt I. Synthesis of sulfenates of sugar derivatives. Carbohydrate Research 222:271-76, 1991. e-Pub 1991.
81. Szeja, Wl, Fokt, I, Grynkiewicz, G. Benzylation of sugar polyols by means of the PTC method. Recueil des Travaux Chimiques des Pays‐Bas 108(6):224-226, 1989. e-Pub 1989.
82. Szeja W, Fokt I, Grynkiewicz G, Fitak H. Chemoselective deprotection of 1-0-Acyl sugar. J. Chem. Research S, 1989. e-Pub 1989.
83. Chmielewski M, Szeja W, Fokt I, Grynkiewicz G, Grodner J. An improved synthesis and NMR data of benzylated glycals. J. Carb. Chemistry 8:735-741, 1989. e-Pub 1989.
84. Szeja W, Fokt I, Grynkiewicz G. Benzylation of sugar polyols by means of the PTC method. Recl. Trav. Chim., Pays-Bas 108:224-228, 1989. e-Pub 1989.
85. Chakraborty A, Guha S, Szymanski S, Fokt I, Helgason T, Kazerooni R, Madden T, Priebe W. WP1066, a novel JAK2-STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. Urology.

Invited Articles

1. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO. Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 340:529-55, 2001. e-Pub 2001. PMID: 11494869.

Other Articles

1. Pajak B, Zielinski R, Manning JT, Matejin S, Paessler S, Fokt I, Emmett MR, Priebe W The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses. Molecules 27(18), 2022. PMID: 36144664.
2. Pajak B, Siwiak E, Soltyka M, Priebe A, Zielinski R, Fokt I, Ziemniak M, Jaskiewicz A, Borowski R, Domoradzki T, Priebe W 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. Int J Mol Sci 21(1), 2019. PMID: 31905745.
3. Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T, Priebe W Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem 8(1):51-64, 2001. PMID: 11172692.

Abstracts

1. Zielinski R, Grela K, Cardenas-Zuniga R, Fokt I, Skora S, Poimenidou M, S-E LC, Ludwig J A, Priebe W. Targeting sarcoma pulmonary metastases with annamycin. CTOS 2021 Annual Meeting, Nov 10-13, 2021, 2021. e-Pub 2021.
2. Zielinski R, Grela K, Cardenas-Zuniga R, Poimenidou M, Remiszewski M, Felix E, Fokt I, Skora S, Priebe W. A highly potent unique DNA binding agent with enhanced CNS uptake. Society of Neuro-Oncology 26th Annual Scientific Meeting, Nov 18-21, 2021 23(6):181, 2021. e-Pub 2021.
3. Zielinski R, Zal T, Grela K, Skora S, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Priebe W. Dose and Schedule-Dependent Efficacy of Liposomal Annamycin in Pre-clinical Models of Acute Myeloid Leukemia. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 18(12), 2019. e-Pub 2019.
4. Zielinski R, Grela K, Skora S, Jacamo R, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Zal MA, Andreeff M, Priebe W, Zal T. Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model. American Society of Hematology (ASH) 134(1), 2019. e-Pub 2019.
5. Zielinski R, Grela K, Skora S, Fokt I, Sander M, Didluch A, Priebe W. Liposomal Annamycin Inhibition of Lung Localized Breast Cancer. San Antonio Breast Cancer Symposium (SABC), 2019. e-Pub 2019.
6. Priebe W, Zielinski, R, Fokt I, Felix E, Aramugam J, Venugopal R, Khuong M, Krasinski M, Skora S. Design and evaluation of WP1122, an inhibitor of glycolysis with increased CNS uptake. Proceedings: 23rd Annual Meeting and Education Day, New Orleans, LA, November 15-18, 2018. Submitted 20(6):vi86, 2018. e-Pub 2018.
7. Zielinski R, Tworowska I, Skora S, Rusin A, Venugopal R, Arumugam J, Fokt I, Kang Y, Fleming J, Huang Y, Herpai D, Debinski W, Priebe W. Targeting IL-13RA2 in melanoma and pancreatic cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA) (#1927) 78(13):Supplement (#1927), 7/2018, 2018. e-Pub 2018.
8. Basu H, Wilgonowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe D, Wilding G. A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3846 78(13):Supplement (#3846), 7/2018, 2018. e-Pub 2018.
9. Priebe W, Zielinski R, Fokt I, Skora S, Jayakumar A, Venugopal R, Felix E. A Novel Approach to the Therapy of Pancreatic Cancer Targeting STAT3. Annual GAP Conference 2018 "Global efforts fighting cancer", Stockholm, Sweden, 5/15/2018. e-Pub 2018.
10. Gue C, Fokt I, Fahrenholtz S, Layman R, Priebe W, Cressman E. Alternatives to ethiodized oil in IR research: From biodiesel to radiopaque oily embolic agent. Proceedings: SIR Annual Scientific Meeting, 3/2018, 2018. e-Pub 2018.
11. Zielinski R, Fokt I, Felix E, Khuong M, Krasinski M, Venugopal R, Arumugam J, Skora S, Priebe W. Preclinical evaluation of WP1122, a 2-DG prodrug and inhibitor of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 10/2017, 2017. e-Pub 2017.
12. Fokt I, Skora S, Cybulski M, Zielinski R, Nguyen V, Felix E, Priebe W. Design, synthesis, and evaluation of 2-DG prodrugs and potentially useful in vivo inhibitors of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 10/2017, 2017. e-Pub 2017.
13. Priebe W, Fokt I, Cybulski M, Zielinski R, Rusin A, Conrad C, Madden T. Latentiation of 2-Deoxy-D-glucose. Proceedings: 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, Germany; Nov 29- Dec 2, 2016 68(Supplement 1), 12/2016. e-Pub 2016.
14. Fokt I, Cybulski M, Skora S, Priebe W. Synthesis of selectively acetylated 2-deoxy-D-glucose, potential agents for treatment of brain tumors. Proceedings: 28th Annual International Carbohydrate Symposium, July 17-21, 2016,; New Orleans,LA. e-Pub 2016.
15. Zielinski R, Fokt I, Rusin A, Skora S, Priebe W. 2-Deoxy-2-halo-D-glucose derivatives inhibition of glycolysis in pancreatic cancer. Cancer Research. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA 76(14). e-Pub 2016.
16. Conrad C, Fokt I, Madden T, Priebe W. An anthracycline analog, WP744, purposely designed to circumvent the blood-brain barrier appears to show activity in patients with recurrent high-grade gliomas in a Phase I study. 2015 SNO-SCIDOT Joint Conference, San Antonio, TX, 2015. e-Pub 2015.
17. Zielinski R, Skora S, Rusin A, Fokt I, Heimberger A, Sawaya R, Priebe W. Combination of topoisomerase II poison Berubicin with. 20th Annual Society for Neuro-Oncology Annual Scientific Meeting, San Antonio, TX, 2015. e-Pub 2015.
18. Priebe W, Cybulski M, Fokt I, Conrad C. Design and Development of Monosaccharide-based Anticancer Drugs. 58th Annual Scientific Meeting of the Polish Chemical Society, Sept 21-25, 2015, Gdansk, Poland:470, 2015. e-Pub 2015.
19. Priebe W, Jayakumar A, Radjendirane V, Fleming J. Transcriptional Control of Pancreatic Cancer and Small Molecule Modulators of Transcription. Proceedings: EACR-AACR-SIC 2015 Special COnference, 20-23 June, 2015, Florence, Italy:28, 2015. e-Pub 2015.
20. Jayakumar A, Venugopal R, Zielinski R, Rusin A, Fokt I, Skora S, Ni X, Duvic M, Priebe W. High sensitivity of cutaneous T-cell lymphoma (CTCL) to CABE, a component of propolis. Proceedings: AACR Annual Meeting 2015, April 18-22, 2015; Philadelphia, PA, 2015. e-Pub 2015.
21. Rusin A, Zielinski R, Fokt I, Nguyen V, Skora S, Jayakumar A, Priebe W. WP760, A new highly potent and selective agent against melanoma including BRAFi resistant melanoma. Proceedings: AACR Annual Meeting 2015, April 18-22, 2015; Philadelphia, PA, 2015. e-Pub 2015.
22. Jayakumar A, Venugopal R, Fleming J, Kang Y, Rusin A, Zielinski R, Skora S, Fokt I, Priebe W. Status of STAT3, STAT5, and NF-κB in pancreatic cancer cell lines, small molecule inhibitors, and potential clinical implications. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 74(21), 2014. e-Pub 2014.
23. Olbryt M, Rusin A, Fokt I, Habryka A, Sochanik A, Priebe W. Anti-melanoma activity of WP760 in various in vitro culturing conditions. Proceedings: 9th Int. Conf. of Anticancer Research, Oct 6-10, 2014, Porto Carras, Greece 34(10):6086-6086, 2014. e-Pub 2014.
24. Zielinski R, Rusin A, Priebe A, Arumugam J, Venugopal R, Skora S, Fokt I, Priebe W. STAT3/STAT5 blockade by WP1066 inhibits ovarian cancer cell proliferation and induces cell death. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 74(21), 2014. e-Pub 2014.
25. Fokt I, Krawczyk M, Kosinski S, Skora S, Cybulski M, Priebe W. Facile, selective one-pot synthesis of 4-O-benzylated glycals. Proceedings: 247th ACS National Meeting, Dallas, TX, 3/2014, 2014. e-Pub 2014.
26. Choi Y, Pandya H, Gibo D, Fokt I, Priebe W, Debinski W. Nucleus-targeted doxorubicin as a potential therapy for glioblastoma. Proceedings: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, Nov 21-24, 2013, San Francisco, CA; #ET-014, 2013. e-Pub 2013.
27. Jayakumar A, Rauvolfova J, Bao H, Fokt I, Skora S, Heimberger A, Priebe W. Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma. AACR annual meeting 2013, 2013. e-Pub 2013.
28. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. 245th ACS National Meeting & Exposition, New Orleans, LA, United States, 2013. e-Pub 2013.
29. Choi Y, Pandya H, Gibo D, Fokt I, Priebe W, Debinski W. Nucleus-targeted doxorubicin as a potential therapy for glioblastoma. Neuro Oncology 15(3):iii37-iii61, 2013. e-Pub 2013.
30. Wang M, Sun L, Fokt I, Zhang L, Jayakumar A, Priebe W. Effect of berubicin, the 4'-o-benzylated doxorubicin analog, on growth inhibition and apoptosis in multiple myeloma. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2012. e-Pub 2012.
31. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
32. Emmett MR, Wang X, Marshall A, Ji Y, Fokt I, Skora S, Conrad C, Priebe W. 2-Deoxy-D-Glucose Inhibits N-glycosylation in Glioblastoma-Derived Cancer. Stem Cells, 2011. e-Pub 2011.
33. Emmett M, Wang X, Marshall A, Ji Y, Fokt I, Skora S, Conrad C, Priebe W. 2-Deoxy-D-glucose inhibits N-Glycosylation in Glioblastoma- Derived Cancer Stem Cells. 15th Annual SNO meeting, Montreal, Canada, 2010. e-Pub 2010.
34. Priebe W, Sun L, Fokt I, Zhang L, Jayakumar A, Zhang X, Madden T, Wang M. Berubicin, a topoisomerase II with high CNS uptake, potently inhibits cell growth and induces apoptosis in diffuse large B-cell lyphomas. 2010 EORTC-NCI-AACR conference, Berlin, Germany, 2010. e-Pub 2010.
35. Fokt I. Glioma cancer stem cells induce immune suppressive macrophages. 100th AACR Meeting, Washington DC, 2010. e-Pub 2010.
36. Fokt, I. Glycolysis: Chemistry, Biology, and Therapeutic Ramification. 239th ACS National Meeting, 2010. e-Pub 2010.
37. Madden T, Johansen MJ, Thapar J, Conrad C, Fokt I, Priebe W. WP769: An orally bioavailable blood brain barrier penetrating anthracycline. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009. e-Pub 2009.
38. Priebe W, Cybulski C, Fokt I, Skora S, Conrad CA, Madden T. Blocking glycolysis with 2-deoxy-D-glucose prodrugs to target brain tumors: A novel concept. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009. e-Pub 2009.
39. Kong LY, Wei J, Gelbard A, Wang T, Wei Q, Fokt I, Overwijk WW, Priebe W, Heimberger AB. STAT-3 Blockade Enhances IFN-alpha Immunotherapy for Intracerebral Malignancy. Neuro-Oncology 11(5):615, 2009. e-Pub 2009.
40. Koul D, Fokt I, Guan S, Conrad CA, Madden T, Yung WKA, Priebe W. Berubicin: A Novel Topoisomerase II Inhibitor with activity In Ependymoma. NEURO-ONCOLOGY 11(5):640, 2009. e-Pub 2009.
41. Ahmed AA, Fokt I, Krzysko K, Lesyng B, Jr BR, Priebe W. Unsaturated glycoside of genistein induces severe microtubule depolymerizaion and mitotic arrest in ovarian cancer cells. 100th American Association for Cancer Research Annual Meeting, 2009. e-Pub 2009.
42. Colman H, Conrad CC, Sai K, Wang S, Popoff S, Aldape K, Lang F, Fokt I, Madden TL, Yung WKA, Priebe W. WP1193 inhibits JAK2/STAT3 pathway, blocks self-renewal and induces apoptosis in glioblastoma cancer stem cells. 100th American Association for Cancer Medicine Annual Meeting, 2009. e-Pub 2009.
43. Antonovic L, Fokt I, Johansen MJ, Szymanski S, Skora S, Conard CA, Madden T, Priebe W. A novel monosaccharide-based antimetabolite 2,2-difluoro-D-glucose (2-DFG) blocks glycolysis and induces cell death in gliomas. 20th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2008. e-Pub 2008.
44. Kazerooni R, Conrad C, Johansen MJ, Sakamoto M, Fokt I, Schroeder C, Thapar N, Meyer C, Priebe W, Madden T. Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin (B), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials. 20th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2008. e-Pub 2008.
45. Fokt, I. WP1066, a Potent Inhibitor of Jak2/STAT3 Pathway, Inhibits Pancreatic Cancer Growth in Both in Vitro and in Vivo. Gastrointestinal Cancer Research 2(4):205-208, 2008. e-Pub 2008.
46. Antonovic L, Fokt I, Szymanski S, Conrad CA, Johansen MJ, Madden TL, Priebe W. 2-Deoxy-2-fluoro-D-mannose induces type II cell death in gliomas. AACR Annual Meeting 2008, 2008. e-Pub 2008.
47. Guha S, Chakraborty A, Kunnumakkara A, Szymanski S, Fokt I, Abbruzzese J, Aggarwal B, Madden T, Priebe W. A novel JAK2-STAT3 inhibitor blocks mitogenesis and angiogenesis in pancreatic cancer. AACR Annual Meeting 2008, 2008. e-Pub 2008.
48. Kazerooni R, Schroeder C, Conrad C, Johansen M, Sakamoto M, Fokt I, Thapar N, Meyer C, Priebe W. Metabolite pharmacokinetics of berubicinol (BRB-ol), the 13-hydroxy metabolite of RTA744 (berubicin(BRB)), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials. AACR Annual Meeting 2008, 2008. e-Pub 2008.
49. Kong LY, Hussain SF, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients. 12th Annual Meeting of the Society of Neuro-Oncology, 2007. e-Pub 2007.
50. Antonovic L, Johansen M, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. 2-Deoxy-D-glucose induces Type II cell death in pancreatic cancer. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA B35, 2007. e-Pub 2007.
51. Schroeder CP, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, Priebe W. WP760, a New DNA-binding agent with unique melanoma selectivity. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA A219, 2007. e-Pub 2007.
52. Antonovic L, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. Inhibition of glycolysis and induction of autophagy in gliomas by 2-fluoro-deoxy-D-glucose. AACR-NCI-EROTC International Conference: Molecular targets amd Cancer Therapeutics, 2007. e-Pub 2007.
53. Guha S, Chakraborty A, Kunumakkara AB, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Aggarwal BB, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2-STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. Gastrointestinal Cancer Research 2(4):205-208, 2007. e-Pub 2007.
54. Madden T, Johansen M, Conrad C, Kazerooni R, Fokt I, Thapar N, Meyer C, Priebe W. WP769: An orally bioavailable topo II poison with activity against brain tumors. 98th AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
55. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, Madden T, Priebe W. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cncer cells. 98th AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
56. Bidwell G, Davis A, Fokt I, Priebe W, Raucher D. An elastin-like polypeptide-doxorubicin fusion for thermally-targeted delivery and evasion of multidrug resistance. 98th AACR Meeting, Los Angeles, CA, 2007. e-Pub 2007.
57. Priebe W, Madden TL, Fokt I, Johansen M, Conrad CA. Modular Design of DNA Binding Agents Capable of Penetrating Blood-Brain Barrier and Targeting Brain Tumors. Chemistry in Cancer Research (AACR special conference), San Diego, 2007. e-Pub 2007.
58. Priebe W, Fokt I, Szymanski S, Bao J, Conrad C, Chakraborty A, Abbruzzese J, Guha S, Myers J, Madden T. Novel small molecule inhibitors of Jak2/STAT3 pathway: design, structure-activity relationship, and oral bioavailability. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006. e-Pub 2006.
59. Fokt I, Priebe W. Synthesis of WP744/RTA744, a New Blood-Brain Barrier (BBB) Penetrating Anthracycline. 62nd SW ACS Regional Meeting, 2006. e-Pub 2006.
60. Conrad C, Madden T, Maher E, Cloughesy T, Meyer C, Priebe W, Baud C, Fokt I, Gilbert M, Groves M, Levin V, Yung WKA. Preliminary Results of an Accelerated Dose Escalation Phase 1 Trial with the Novel Anthracycline Derivative (RTA 744) in Patients with Primary Brain Tumors. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006. e-Pub 2006.
61. Waldemar P, Fokt I, Szymanski S, Madden T, Bao JI, Lesyng B, Conrad C, Kupferman M, Abbruzzese J, Myers J. Design, Synthesis and Structure-Activity Relationships of Novel Jak2/STAT3 Signaling Inhibitors. 97th AACR Annual Meeting 47:LB-298, 2006. e-Pub 2006.
62. Fanale MA, Liu Y, McKenzie TS, Fokt I, Priebe W, Hunt KK. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. J Clinical Oncology, ASCO Meeting Abstracts Jun 1 2005: 2082 23(26):155S-155S Part 1 Suppl. S, 2005. e-Pub 2005.
63. Fokt I, Conrad CA, Madden T, Yung AW, Lang FF, Thapar N, Priebe W. The discovery and development of blood-brain barrier (BBB) penetrating anthracyclines for the treatment of brain tumors. Clinical Cancer Research 11(24):9013S-9013S, 2005. e-Pub 2005.
64. Fokt I, Conrad C, Madden T, Yung AW, Lang FF, Thapar N, Priebe W. The discovery and Development of Blood-Brain Barrier (BBB) Penetrating Anthracyclines for the Treatment of Brain Tumors. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
65. Thapar N, Priebe W, Johansen MJ, Fokt I, Thapar J, Meyer C, Conrad CA, Madden T. Summary of the Preclinical Pharmacology of RTA 744 (WP744): A New Topo II Inhibitor in Phase I Development. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
66. Fanale MA, Liu TS, McKenzie TS Fokt I, Priebe W, Hunt KK. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. 2005 ASCO Annual Meeting, Florida, 2005. e-Pub 2005.
67. Iwamaru A, Szymanski S, Fokt I, Hess KR, Sawaya R, Kondo S, Priebe W, Kondo Y. Inhibition of STAT3 signaling by WP1066, a novel tyrosine kinase inhibitor in malignant glioma cells in vivo. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
68. Thapar NC, Priebe W, Johansen MJ, Fokt I, Thapar J, Meyer C, Conrad CA, Madden T. Summary of the preclinical pharmacology of RTA 744 (WP744): A new topo II inhibitor in phase I development. Clinical Cancer Research 11(24):9019S-9020S, 2005. e-Pub 2005.
69. Bao JJ, Fokt I, Szymanski S, Priebe W, Madden T, Conrad C, Abbruzzese J. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clinical Cancer Research 11(24):9026S-9027S, 2005. e-Pub 2005.
70. Bao YI, Fokt I, Szymanski S, Madden T, Conrad C, Abbruzzese J, Priebe W. Inhibition of Consititutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
71. Lee S, Fokt I, Grossman HB, Czerniak B, Dinney C, Priebe W. WP744, a novel anthracycline highly active against wild-type and doxorubicin-resistant bladder cancer cell lines. Proc 96 Am Assoc Cancer Res, 46: 2389, 2005. e-Pub 2005.
72. Iwamaru A, Szymanski SP, Fokt I, Priebe W, Hess KR, Sawaya R, Kondo Y. Inhibition of STAT3 signaling by WP1066, a novel tyrosine kinase inhibitor in malignant glioma cells in vitro and in vivo. Clinical Cancer Research 11(24):9021S-9021S, 2005. e-Pub 2005.
73. Fokt ID, Kowalczyk-Przewloka T, Skora S, Kosior M, Pastuch G, Wandzik I, Grynkiewicz G, Szeja W, Priebe W. Practical synthesis of WP744, a brain tumor-targeting anthracycline. 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26 Abstracts of Papers, 2004. e-Pub 2004.
74. Fokt ID, Mironiuk E, Dominiak P, Pastuch G, Wozniak K, Priebe W. Facile synthesis of 14-, 16-, and 18-member macrocycles from configurationally diverse sugars. 228th ACS National Meeting, CARB-51, Philadelphia Abstracts of Papers, 2004. e-Pub 2004.
75. Fokt ID, Mironiuk E, Dominiak P, Pastuch G, Wozniak K, Priebe W. Facile synthesis of 14-, 16-, and 18-member macrocycles from configurationally diverse sugars. 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26 Abstracts of Papers, 2004. e-Pub 2004.
76. Krawczyk, Marta, Kosinski, Szymon, Fokt, Izabela D, Priebe, Waldemar. Selective benzylation of glycals. 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26 Abstracts of Papers, 2004. e-Pub 2004.
77. Fokt I, Krawczyk M, Skibicki P, Grynkiewicz G, Priebe W. Sugar moiety-fluorinated anthrycyclines. 233rd ACS National Meeting, Chicago, IL, 2004. e-Pub 2004.
78. Thapar, N Scholz CR, Johansen MJ, Conrad C, Priebe W, Thapar J, Fokt I, Cullota K, Madden T. CNS distribution of WP744; A novel anthracyclines with activity against glioblastoma multiforme. Proc. 95 Am. Assoc. Cancer Res., 45: 5406, March 27-31, 2004, Orlando 45:5406, 2004. e-Pub 2004.
79. Fanale M, Liu Y, McKenzie T, Fokt I, Priebe W, Hunt K. WP744, a novel anthracycline highly apoptotic in breast cancer cells. Proc. 95 Am. Assoc. Cancer Res., 45: 3843, March 27-31, Orlando 45:3843, 2004. e-Pub 2004.
80. Lampidis TJ, Szymanski S, Fokt I, Ping H, Rudnicki A, Ginalski K, Lesyng B, Priebe W. Growth inhibitory effects of 2-halo analogs of 2-deoxy-D-glucose on hypoxic tumor cells. Proc. 95 Am. Assoc. Cancer Res., 45: 1005, March 27-31, Orlando 45:1005, 2004. e-Pub 2004.
81. Fokt ID, Kowalczyk-Przewloka T, Skora S, Kosior M, Pastuch G, Wandzik I, Grynkiewicz G, Szeja W, Priebe W. Practical synthesis of WP744, a brain tumor-targeting anthracycline. 228th ACS National Meeting, CARB-52, Philadelphia Abstracts of Papers, 2004. e-Pub 2004.
82. Krawczyk M, Kosinski S, Fokt ID, Priebe W. Selective benzylation of glycals. 228th ACS National Meeting, CARB-53, Philadelphia, 2004. e-Pub 2004.
83. Inge TH, Harris NL, Azizkhan RG, Wu J, Fokt I, Priebe W. WP744 overcomes doxorubicin resistance in neuroblastoma cells. Proc. 94 AACR 94th Meeting, July 10-14, Washington (2nd ed.), 44:1616, 2003. e-Pub 2003.
84. Wu Q, Vega J, Cao X, Wallace S, Fokt I, Priebe W, Li C. Antitumor activity of doxorubicin (DOX)-bound polyethylene glycol-poly(L-glutamic acid) (PEG-PG) block copolymer with amide and ester linkages. Proc. 94 Am. Assoc. Cancer Res. (2nd ed.), 44: 1656, July 10-14, Washington 44:1656, 2003. e-Pub 2003.
85. Brooks TA, Vredenburg M, Pera P, Fokt I, Priebe W, Bernacki RJ. WP744, an anthracycline analog active against multidrug resistant cell lines. Proc. 94 Am. Assoc. Cancer Res. (2nd ed.), 44: R1617, July 10-14, Washington 44, 2003. e-Pub 2003.
86. Priebe W, Evrony G, Fokt I, Lee S, Talpaz M, Donato NJ. WP744, A Novel Highly Apoptotic and Anti-Proliferative Agent against STI-571-Resistant Leukemic Cells. 3rd International Conference on Inhibitors of Protein Kinases. Warsaw, June 22-27, 2003. e-Pub 2003.
87. Scholz CR, Thapar NC, Johansen MJ, Fokt I, Culotta KS, Priebe W, Madden TL. A Sensitive and Specific Method for the Determination of WP744, a Mechanistically Altered Anthracycline in Mouse, Rat, Dog, and Human Plasma by LC/MS/MS., . AACR-NCI-EORTC #C241:243, 2003. e-Pub 2003.
88. Thapar NC, Scholz CR, Fokt I, Johansen MJ, Rhea R, Thapar JK, Priebe W, Madden T. Preclinical investigation of the oral bioavailability, pharmacokinetics, and tissue distribution of WP769, a new potent topoisomerase II poison. AACR-NCI-EORTC, 2003. e-Pub 2003.
89. Thapar NC, Scholz CR, Fokt I, Johansen MJ, Rhea R, Neil C, Priebe W, Madden T. Preclinical Pharmacokinetics of WP744, a novel promising anticancer agent. AACR-NCI-EORTC, 2003. e-Pub 2003.
90. Fokt ID, Priebe W, Grynkiewicz G. Synthesis of WP744, a novel highly apoptotic anticancer agent. 226th ACS National Meeting, CARB-064, New York, NY, 2003. e-Pub 2003.
91. Priebe W, Fokt I, Lee S, Young A, Lang FF, Madden T, Conrad CA. Targeting glioblastoma with new DNA-Binding Agents. AACR-NCI-EORTC, 2003. e-Pub 2003.
92. Kong LY, Talpaz M, Priebe W, Levitzki A, Aggarwal B, Fokt I, Szymanski S, Donato NJ. Novel Tyrphostin Analogues Inhibit Stat3 Activation and Induce Apoptosis in Multiple Hematological Malignancies. 46th Annual Meeting of American Society of Hematology, San Diego, CA Abstract 4534, 2003. e-Pub 2003.
93. Priebe W, Evrony G, Fokt I, Lee S, Talpaz M, Donato NJ. WP744, A Novel Anthracycline Highly Active Against STI-571 Resistant Tumors. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 19-22, Frankfurt, Germany, 2002. e-Pub 2002.
94. Priebe W, Ashikawa K, Fokt I, Inge T, Aggarwal BB. Nuclear Factor-kB Activation. A New Target for Drug Design?. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 19-22, Frankfurt, Germany. Eur. J. Cancer 38 (Suppl. 7):351, 2002. e-Pub 2002.
95. Priebe W, Evrony G, Fokt I, Talpaz M, Donato NJ. WP744, a novel anthracycline with enhanced apoptotic and antiproliferative activity on STI-571 resistant leukemic cells: Design, synthesis, and evaluation. AACR, 93rd Annual Meeting, April 6-10, San Francisco, 2002. e-Pub 2002.
96. Priebe W, Fokt I, Wozniak K, Dominiak PM, Pastuch G. Synthesis of Macrolides from Functionalized Glycals. Proc. Am. Chem. Soc. Meet.: CARB-42, August 18-22, Boston, MA, 2002. e-Pub 2002.
97. Kirken RA, Nagy Z, Stepkowski SM, Kosinski S, Fokt I, Kahan BD, Priebe W. Targeting Jak3 with Small Molecules to Inhibit T-cell Proliferation. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 19-22, Frankfurt, Germany. Eur. J. Cancer 38(Suppl. 7):353, 2002. e-Pub 2002.
98. Fokt I, Chaires JB, Priebe W. Synthesis of WP 901, an enantiomer of doxorubicin, and its Z-DNA selective binding. Proceedings of The XXIst International Carbohydrate Symposium, Cairns, Australia, July 7-12, 2002. e-Pub 2002.

Book Chapters

1. Priebe W, Fokt I, Grynkiewicz G. Glycal Derivatives, Synthesis and Chemical Reactions. In: Fraser-Reid, Tatsuta, Thiem (Eds.). Glycoscience - Chemistry and Chemical Biology, 1-38, 2007.
2. Grynkiewicz G, Achmatowicz O, Fokt I, Priebe W, Ramza J, Szechner B, Szeja W. Synthesis of natural and modified anthracycline antibiotics from a common precursor: 3,4-di-O-acetyl-L-rhamnal. In: Wiadomosci Chemiczne, 535-560, 2002.
3. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO. Exploiting the Anthracycline Scaffold for Designing DNA-Targeting Agents. In: Methods of Enzymology. Waring. Academic Press, 529-555, 2001.